Clinical trials: Thrombotic Microangiopathies
Primary Immune Thrombocytopenia
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with…
- Trial name
- VAYHIT2 (NCT05653219)
- Testing
- Ianalumab, Eltrombopag
- Where
- 74 sites in United States, Argentina and 22 more
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Acquired Thrombotic Thrombocytopenic Purpura
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
The interpretation of platelet counts has to be revaluated in the light of caplacizumab. By effectively blocking platelet binding sites on VWF-multimers, the nanobody leads to a rapid normalization of the platelet count within 3…
- Trial name
- PREDICT2020 (NCT05876221)
- Testing
- Cablivi
- Where
- Germany
- Volunteers
- 223 people
- Sponsor
- University of Cologne
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small…
- Trial name
- NCT00726544
- Testing
- ARC1779 Injection
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 100 people
- Sponsor
- Archemix Corp.
Idiopathic Thrombocytopenic Purpura
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250×109/L
- Trial name
- NCT03222843
- Testing
- Hetrombopag Olamine
- Where
- 3 sites in China
- Volunteers
- 424 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Thrombotic Thrombocytopenic Purpura
A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura Patients
A prospective cohort study of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome patients who have presented with their acute episode and are in remission within the last 30 days.
- Trial name
- TTP (NCT03187652)
- Testing
- CT Perfusion Study, Echocardiogram, neuro-cognitive assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP).
- Trial name
- ITP^2 (NCT00991939)
- Testing
- Dexamethasone USP Micronized, Prednisone
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Carelon Research
Idiopathic Thrombocytopenic Purpura (ITP)
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
The purpose of this research study is to compare the efficacy and safety of higher doses of rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine, and Prednisone) in patients with chronic…
- Trial name
- NCT00161564
- Testing
- Rituximab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Immune Thrombocytopenic Purpura, Autoimmune Thrombocytopenia
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
This study aims to determine the hemato-immunological parameters predictive of the evolution of a Immune thrombocytopenic purpura (ITP) towards chronicity, and to identify possible differences between the child and the adult.
- Conditions
- Immune Thrombocytopenic Purpura, Autoimmune Thrombocytopenia, Thrombopenia
- Trial name
- IMMUNOTI (NCT04070599)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Idiopathic Thrombocytopenic Purpura
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level
1. The purpose of this study is to investigate the expression of CD11a on subpopulation of lymphocytes and compared its expression between ITP patients and healthy controls and explores its possible role in the pathogenesis of…
- Trial name
- NCT03864796
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Immune Thrombocytopenic Purpura
Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)
Symptoms of Primary Immune Thrombocytopenic Purpura (pITP), such as spontaneous bruising, menorrhagia, mucosal bleeding and other symptoms might significantly affect the HRQOL of pITP patients.
- Trial name
- NCT01510873
- Testing
- HRQOL evaluation
- Where
- 29 sites in Italy
- Volunteers
- 424 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Primary Immune Thrombocytopenia (ITP)
rhTPO Dose Escalation vs Eltrombopag Switch in ITP
This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT < 30×10⁹/L).
- Trial name
- NCT07476846
- Testing
- Recombinant Human Thrombopoietin（rhTPO）, Eltrombopag PfOS
- Volunteers
- 112 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemolytic Uremic Syndrome of Childhood
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still no efficient specific therapy in that potentially devastating…
- Trial name
- ECULISHU (NCT02205541)
- Testing
- Eculizumab
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Idiopathic Thrombocytopenic Purpura
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
The purpose of this study is to describe the effect of anti-D on symptoms and platelet count in children suffering from unexplainable low platelet counts, when anti-D is administered as an injection under the skin.
- Trial name
- NCT00128882
- Testing
- Anti-D
- Where
- 17 sites in Denmark
- Volunteers
- 45 people
- Sponsor
- University of Aarhus
Idiopathic Thrombocytopenic Purpura
Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
This study is designed to investigate the safety of a single infusion of GMA161 in patients with idiopathic thrombocytopenic purpura, as well as, the way the drug enters and leaves the body.
- Trial name
- NCT00244257
- Testing
- GMA161
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company
Immune Thrombocytopenia
RP% Measurement by FCM as a Diagnostic Test for ITP
Immature platelets-also termed reticulated platelets (RP)-are platelets newly released into the circulation, and have been associated with a variety of pathological bleeding events including primary immune thrombocytopenia (ITP).
- Trial name
- NCT02967328
- Testing
- RP% Measurement by FCM as a Diagnostic Test for ITP
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shandong University
Immune Thrombocytopenia, Thrombocytopathy
Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies
The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.
- Conditions
- Immune Thrombocytopenia, Thrombocytopathy, Acute Leukemia, Hemorrhagic Disorders
- Trial name
- NCT05654766
- Testing
- Flow cytometry, Platelet aggregation and plasma coagulation
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Immune Thrombocytopenia
An Investigation of rhTPO With Different Frequencies in the Management of ITP
The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to study the efficacy and safety of different dose and frequency Recombinant Human thrombopoietin in treating…
- Trial name
- NCT02139501
- Testing
- Recombinant Human Thrombopoietin (rhTPO)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shandong University
Thrombotic Thrombocytopenic Purpura (TTP)
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder that some people are born with. It is caused by inherited changes in the ADAMTS13 gene that reduce the body's ability to produce the ADAMTS13 enzyme.
- Trial name
- NCT07429942
- Testing
- No Intervention
- Where
- 8 sites in Germany, Poland
- Volunteers
- 94 people
- Sponsor
- Takeda
Immune Thrombocytopenia
A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
Decitabine has been reported to have a clinically significant, often long lasting effect on the platelet count in myelodysplastic syndromes(MDS).
- Trial name
- NCT01568333
- Testing
- Decitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shandong University